RESUMEN
In 2013, a 118-day study was initiated to investigate the efficacy of concurrent treatment at pasture turnout with an injectable macrocyclic lactone with activity up to 28 days and an oral benzimidazole, referred to as "conventional" anthelmintics, when compared to treatment with conventional macrocyclic lactone alone or an injectable macrocyclic lactone with extended activity of 100 days or longer. A group of 210 steers were obtained from a ranch in California and transported to Idaho, USA. A total of 176 steers with the highest fecal egg counts were blocked by pre-treatment body weights and pasture location. A total of 44 pasture paddocks were assigned with 4 steers per paddock with 12 paddocks per therapeutic treatment group and 8 paddocks per controls. The four treatments were injectable doramectin (Dectomax®, Zoetis Inc., 0.2â¯mgâ¯kg-1BW, SC), injectable doramectin concurrently with oral albendazole (Valbazen®, Zoetis Inc., 10â¯mgâ¯kg-1BW, PO), extended release injectable eprinomectin (LongRange™, Merial Limited, 1â¯mgâ¯kg-1BW, SC) or saline. Cattle were individually weighed and sampled for fecal egg count on Days 0, 31/32, 61, 88, and 117/118 with an additional fecal sample on Day 14. At conclusion, one steer per paddock was euthanized for nematode recovery. The results from the first 32 days found evidence of macrocyclic lactone resistance against injectable doramectin and extended release eprinomectin. During this period the concurrent therapy provided nearly 100% efficacy based on fecal egg count reduction and a 19.98% improvement in total weight gain compared to controls (Pâ¯=â¯0.039). At the conclusion of the 118-day study and past the approved efficacy for the conventional anthelmintics, the concurrent therapy with conventional anthelmintics provided a 22.98% improvement in total weight gain compared to controls (Pâ¯=â¯0.004). The 118-day improvement in weight gain for the extended release eprinomectin group (29.06% compared to control) was not statistically different from the concurrent therapy with conventional anthelmintics. The results indicate that concurrent treatment with a conventional macrocyclic lactone and benzimidazole may provide production benefits early in the grazing period that continue throughout the entire period for cattle harboring macrocyclic lactone resistant nematodes. By using two different anthelmintic classes together, macrocyclic lactone resistant parasites were effectively controlled early in the period. Furthermore, the use of an effective conventional anthelmintic treatment regimen without an extended period of drug release may help to promote refugia and decrease the further selection for anthelmintic resistant parasites.
Asunto(s)
Antihelmínticos/uso terapéutico , Bencimidazoles/uso terapéutico , Enfermedades de los Bovinos/tratamiento farmacológico , Lactonas/uso terapéutico , Nematodos/efectos de los fármacos , Infecciones por Nematodos/veterinaria , Animales , Antihelmínticos/administración & dosificación , Antihelmínticos/efectos adversos , Bencimidazoles/administración & dosificación , Bencimidazoles/efectos adversos , Peso Corporal/efectos de los fármacos , Bovinos , Enfermedades de los Bovinos/parasitología , Resistencia a Múltiples Medicamentos , Quimioterapia Combinada/métodos , Heces/parasitología , Herbivoria , Lactonas/administración & dosificación , Lactonas/química , Infecciones por Nematodos/tratamiento farmacológico , Infecciones por Nematodos/parasitología , Recuento de Huevos de Parásitos/veterinaria , Resultado del Tratamiento , Aumento de Peso/efectos de los fármacosRESUMEN
Two studies evaluated growth promoting effects of implant pellets (IP), each containing 3.5 mg estradiol benzoate (EB) and 25 mg trenbolone acetate (TBA), to which a polymeric, porous coating was applied. Trial 1 evaluated performance of heifers (n = 70/treatment, initial BW = 188 ± 2.2 kg) and steers (n = 70/treatment, initial BW = 194 ± 2.2 kg) implanted subcutaneously in the ear with 0 (SC), 2 (2IP), 4 (4IP), or 6 (6IP) pellets that delivered EB/TBA (mg/mg) doses of 0/0, 7/50, 14/100, and 21/150, respectively, over grazing periods of 202 d (heifers) or 203 d (steers). Animals received experimental treatments on d 0 and over the grazing period were managed as single groups by sex in a rotational grazing system. When pasture forage availability became limited, cattle were supplemented with preserved forage but not concentrate supplements. Weight gains by heifers treated with 2IP, 4IP, and 6IP were greater (P < 0.05) than SC heifers but not different from each other. Weight gains by steers treated with 2IP, 4IP, and 6IP were greater than SC steers (P < 0.05), and ADG by steers treated with 6IP was greater (P < 0.05) than steers given 2IP or 4IP. Trial 2 was a multisite grazing study performed with heifers and steers to compare ADG after treatment with one 6-pellet, coated implant delivering 21 mg EB and 150 mg TBA (6IP) to sham treated negative controls (SC) over a grazing period of at least 200 d. A completely random design was used at each site, with the goal to treat 70 cattle per site, treatment, and sex; data were pooled across sites. Heifers (n = 558, initial BW = 229 ± 16 kg) and steers (n = 555, initial BW = 235 ± 20 kg) grazed in rotational programs consistent with regional practices for an average of 202 d. When necessary, cattle were supplemented with preserved forage, but no concentrate supplements were fed. Over 202 d, ADG by heifers treated with 6IP was 11.3% greater (P = 0.0035) than SC heifers (0.64 ± 0.06 kg/d), and ADG by steers treated with 6IP was 17.2% greater (P = 0.0054) than SC steers (0.66 ± 0.08 kg/d). In neither study was there evidence that concurrent therapeutic treatments or abnormal health observations were influenced by experimental treatments. These studies demonstrated that a 6-pellet implant with a polymeric, porous coating that delivers 21 mg EB and 150 mg TBA improved ADG by grazing heifers and steers for at least 200 d compared to sham-implanted negative controls.
Asunto(s)
Bovinos/crecimiento & desarrollo , Estradiol/análogos & derivados , Herbivoria/fisiología , Acetato de Trembolona/administración & dosificación , Acetato de Trembolona/farmacología , Aumento de Peso/efectos de los fármacos , Crianza de Animales Domésticos/métodos , Fenómenos Fisiológicos Nutricionales de los Animales , Animales , Bovinos/fisiología , Relación Dosis-Respuesta a Droga , Implantes de Medicamentos , Oído , Estradiol/administración & dosificación , Estradiol/farmacología , Femenino , Masculino , Polímeros , Factores Sexuales , Factores de Tiempo , Resultado del Tratamiento , Aumento de Peso/fisiologíaRESUMEN
Trials were conducted with beef heifers at 4 sites to evaluate feedlot performance and carcass characteristics in response to implants containing 14 mg estradiol benzoate and 100 mg trenbolone acetate (EB/TBA; Synovex Choice, Zoetis LLC, New York, NY), 14 mg estradiol benzoate (EB), 100 mg trenbolone acetate (TBA), or a sham-implanted control (SC). The study design at each site was a randomized complete block with 12 blocks and 4 treatments. Blocks of cattle at each site were harvested in commercial abattoirs when masked personnel estimated at least 60% of animals would yield carcasses with USDA quality grades of Choice or Prime. Data were pooled across sites for statistical analysis. Initial BW averaged 374 kg, and days on feed ranged from 98 to 126 d (mean 112 d). Heifers implanted with EB/TBA, EB, and TBA had greater ADG and G:F (P < 0.05) than SC; ADG and G:F were greater for EB/TBA than EB or TBA (P < 0.05). Heifers treated with TBA had greater G:F than EB (P < 0.05). Feed intake was not affected by treatments. Mean HCW and LM area for EB/TBA were greater than for other treatments (P < 0.05). Mean HCW for TBA was greater than SC (P < 0.05) but not different from EB. Mean LM area for EB and TBA were greater than SC (P < 0.05) but not different from each other. There were no treatment differences (P > 0.05) for KPH, 12th-rib fat thickness, or yield grade. Dressing percent was greater for EB/TBA than SC (P < 0.05) but not different from EB or TBA. Marbling score was decreased by EB/TBA (P < 0.05) compared with other treatments, but no other differences were noted. Despite the effect of EB/TBA on marbling scores, there were no significant (P > 0.05) treatment differences on proportions of carcasses with quality grades ≥ Choice vs. < Choice. With respect to ADG and G:F, implants containing EB, TBA, or EB/TBA produced improved responses over SC. Furthermore, EB/TBA induced greater ADG and G:F responses than EB and TBA. Results confirmed that EB and TBA have additive effects, as evidenced by the observation that calves implanted with EB/TBA had significantly greater ADG and G:F than heifers implanted with either EB or TBA alone or compared with SC heifers.
Asunto(s)
Composición Corporal/efectos de los fármacos , Bovinos/crecimiento & desarrollo , Estradiol/análogos & derivados , Acetato de Trembolona/farmacología , Anabolizantes/administración & dosificación , Anabolizantes/farmacología , Animales , Combinación de Medicamentos , Implantes de Medicamentos , Estradiol/administración & dosificación , Estradiol/farmacología , Estrógenos/administración & dosificación , Estrógenos/farmacología , Femenino , Acetato de Trembolona/administración & dosificaciónRESUMEN
Synovex Plus (SP) is a product that delivers 28 mg of estradiol benzoate (EB) and 200 mg of trenbolone acetate (TBA). We studied the impact of a polymeric, porous coating on SP implants (CSP) to prolong release of EB and TBA, and stimulate feedlot performance of feedlot cattle for an extended period. In an explant study, 30 steers were implanted with SP in one ear and CSP in the contralateral ear. Cattle (n = 6/d) were necropsied 40, 81, 120, 160, and 200 d after treatment, and remaining EB and TBA were quantified. Linear regression of EB and TBA remaining as a function of time for each treatment were computed. Rates of EB and TBA depletion from SP were -0.1980 (r(2) = 0.9994) and -1.7073 mg/d (r(2) = 0.9644), respectively, and for CSP rates of EB and TBA depletion were -0.1049 (r(2) = 0.9123) and -0.9466 mg/d (r(2) = 0.9297), respectively. The effect of treatment on depletion rates of each analyte were significant (P < 0.05). Data also showed EB and TBA were delivered from CSP at least 200 d but were delivered from SP about 120 d. Multisite trials with beef-type steers (4 sites) and heifers (4 sites) evaluated feedlot performance and carcass characteristics in response to a CSP implant or when sham implanted (SC). A randomized complete block design with 9 blocks and 2 treatments was used per site within animal gender. Across sites, steers (n = 342, BW = 297 kg) were fed finishing rations for 190 to 202 d (mean 198 d) and heifers (n = 342, BW = 289 kg) were fed finishing rations for 191 to 201 d (mean 198 d). Cattle were harvested and carcasses evaluated. Data were pooled across sites within gender for statistical analysis. Steers and heifers treated with CSP yielded greater (P ≤ 0.003) ADG, DMI, and G:F than SC steers and heifers. Mean BW differences between CSP and SC continued to increase throughout the study, indicating CSP stimulated growth of steers and heifers for 198 d. Mean carcass weights of CSP steers (P = 0.005) and heifers (P = 0.004) were greater than those of SP steers and heifers by 26.2 and 20.6 kg, respectively. The LM area was larger (P < 0.001) in CSP steers and heifers than SC cattle. Marbling decreased with CSP treatment (P ≤ 0.031), which caused reductions (P ≤ 0.006) in proportions of carcasses grading Prime or Choice. Evidence from these studies showed that a single administration of CSP increased feedlot cattle performance for at least 198 d, compared with SC, and may reduce the need to reimplant cattle.
Asunto(s)
Adyuvantes Farmacéuticos/administración & dosificación , Anabolizantes/administración & dosificación , Bovinos/crecimiento & desarrollo , Bovinos/metabolismo , Estradiol/análogos & derivados , Acetato de Trembolona/administración & dosificación , Crianza de Animales Domésticos , Animales , Combinación de Medicamentos , Implantes de Medicamentos/administración & dosificación , Estradiol/administración & dosificación , Femenino , Masculino , Factores de TiempoRESUMEN
In June 2008, 122 yearling heifers with a history of anthelmintic resistance were obtained from pastures in northern California and transported to a dry lot facility in southwestern Idaho, USA. Fifty heifers with the highest fecal egg counts were selected for study enrollment. Candidates were equally randomized to treatment with either injectable ivermectin (Ivomec, Merial, 0.2 mg kg(-1) BW), injectable moxidectin (Cydectin), Fort Dodge, 0.2 mg kg(-1) BW), oral fenbendazole (Safe-Guard), Intervet, 5.0 mg kg(-1) BW), oral oxfendazole (Synanthic), Fort Dodge, 4.5 mg kg(-1) BW), or saline. At 14 days post-treatment, nematodes were recovered from the abomasum, small intestine, and large intestine. Parasitism was confirmed in the control group when 10/10 animals were infected with adult Ostertagia ostertagi and 9/10 animals with both developing and early L(4) stages of O. ostertagi. Similarly, 9/10 animals were parasitized with adult Cooperia spp. Fenbendazole and oxfendazole efficacy verses controls were >90% against adult Cooperia spp., while moxidectin caused an 88% parasite reduction post-treatment (P<0.05). Ivermectin treatment resulted in no reduction in adult Cooperia spp. Based on geometric mean percent reduction versus saline controls, all four treatments were >or=90% efficacious against adults of O. ostertagi, while moxidectin and fenbendazole were equally effective against developing and inhibited early L(4) stages (P<0.05). Ivermectin was not efficacious for developing or inhibited early L(4) stages of O. ostertagi. Oxfendazole failed to decrease O. ostertagi developing L(4) larvae by >90% but was efficacious for inhibited early L(4) larvae. Based on the results of this study, a source of multi-species anthelmintic resistance in cattle has been identified in the western United States.
Asunto(s)
Antihelmínticos/farmacología , Enfermedades de los Bovinos/parasitología , Resistencia a Medicamentos , Trichostrongyloidea/efectos de los fármacos , Tricostrongiloidiasis/veterinaria , Animales , Antihelmínticos/uso terapéutico , California/epidemiología , Bovinos , Enfermedades de los Bovinos/tratamiento farmacológico , Enfermedades de los Bovinos/epidemiología , Heces/parasitología , Femenino , Lactamas Macrocíclicas/farmacología , Tricostrongiloidiasis/epidemiología , Tricostrongiloidiasis/parasitologíaRESUMEN
Controlled trials with a common protocol were conducted in Idaho, Illinois and Tennessee to evaluate anthelmintic effectiveness of Quest Gel (QG; 2% moxidectin) against lumenal parasites in horses. Candidate horses were required to have naturally acquired nematode infections, as confirmed by presence of strongylid eggs in feces. At each site, 24 equids were blocked on the basis of pretreatment strongyle fecal egg counts (EPG) and randomly assigned to treatments within blocks. Within each block of two animals, one received QG on Day 0 at a dosage of 0.4 mg moxidectin/kg b.w. and one was an untreated control. Body weights measured the day before treatment served as the basis for calculating treatment doses. Horses assigned to treatment with QG received the prescribed dose administered orally with the commercially packaged Sure Dial syringe. Horses were necropsied 12-14 days after treatment, and lumenal parasites and digesta were harvested separately from each of five organs, including the stomach, small intestine, cecum, ventral colon and dorsal colon. Parasites from stomachs and small intestines were identified to genus, species and stage. Micro- (i.e., < 1.5 cm) and macroparasites (i.e., > 1.5 cm) in aliquots from the cecum, ventral colon and dorsal colon were examined in aliquots of approximately 200 parasites until at least 600 parasites had been identified to genus, species and stage or until all parasites in the 5% aliquot were examined, whichever occurred first. Data were combined across sites and analyzed by mixed model analysis of variance to assess the fixed effect of treatment and random effects of site and block within site. Because QG does not contain a cestocide, efficacy of QG against tapeworms was not significant (P > 0.05). Based on geometric means, however, efficacy of QG was greater than 90% (P < 0.05) against 38 species and developmental stages of cyathostomes, strongyles, bots, larval pinworms and ascarids encountered in at least 6 of 36 control horses in the combined data set. None of the horses treated with moxidectin exhibited evidence of adverse effects. Study results demonstrate QG, administered to horses with naturally acquired endoparasite infections at a dosage of 0.4 mg moxidectin/kg b.w., was highly effective against a broad range of equine parasitic infections.
Asunto(s)
Antihelmínticos/uso terapéutico , Helmintiasis Animal/tratamiento farmacológico , Enfermedades de los Caballos/tratamiento farmacológico , Análisis de Varianza , Animales , Relación Dosis-Respuesta a Droga , Heces/parasitología , Femenino , Caballos , Macrólidos/uso terapéutico , Masculino , Especificidad de Órganos , Recuento de Huevos de Parásitos/veterinaria , Distribución Aleatoria , Resultado del TratamientoRESUMEN
This study was performed to test the hypothesis that immunity to heterologous vaccination would improve when the parasites were removed. It was also expected that parasitised ponies would exhibit a biased Th2 cytokine response to KLH immunisation. Helminth parasites are common in horses even in the era of highly effective broad-spectrum antiparasiticides. These parasites have been shown to alter the outcome to heterologous immunisation in a number of host species. The effect of gastrointestinal parasites on heterologous vaccination has not been addressed in equids. In the current study, humoral, lymphoproliferative, and cytokine responses to a single i.m. injection of keyhole limpet haemocyanin (KLH) were compared between groups of ponies with high, medium or low gastrointestinal parasite burdens. Antibody levels determined by ELISA showed that animals with low levels of parasites had a trend toward increased KLH specific total immunoglobulin, IgG(T) and IgA compared to heavily parasitised ponies. Medium and heavily parasitised ponies demonstrated a trend toward reduced lymphoproliferative response to KLH that was not restored after the addition of interleukin-2 (Il-2). Cells from these ponies also produced significantly lower levels of IL-4 compared to lightly parasitised ponies. These data indicate that heavily parasitised ponies have uniformly decreased cellular and humoral immune responses to soluble protein immunisation. The mechanisms involved may have potential deleterious effects on standard vaccine protocols of parasitised equines.
Asunto(s)
Adyuvantes Inmunológicos/administración & dosificación , Sistema Digestivo/parasitología , Helmintiasis Animal/inmunología , Hemocianinas/administración & dosificación , Enfermedades de los Caballos/inmunología , Animales , Formación de Anticuerpos , Citocinas/biosíntesis , Citocinas/inmunología , Ensayo de Inmunoadsorción Enzimática/veterinaria , Helmintiasis Animal/parasitología , Helmintos , Hemocianinas/inmunología , Enfermedades de los Caballos/parasitología , Caballos , Inmunoglobulina A/inmunología , Inmunoglobulina G/inmunología , Inyecciones Intramusculares/veterinaria , Interleucina-2/administración & dosificación , Interleucina-2/inmunología , Activación de Linfocitos , Distribución AleatoriaRESUMEN
Two observers performed simple reaction-time responses to peripheral stimuli of varying intensity (-2.5 to +1.0 log td) and angular subtense (10 to 210 min). The area-intensity combinations that produced each of three scotopic reaction-time criteria were calculated. Analysis of these combinations showed that the area-intensity reciprocity could not be predicted by traditional theories of spatial summation. Like earlier findings for peripheral photopic reaction-time criteria, the results indicated that for small stimulus sizes, area has a greater effect than intensity in determining the scotopic reaction-time responses.